Latest Period
Q1 2026
Security Snapshot
RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (RLMD) Institutional Ownership
CUSIP: 75955J402
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
102
Shares (Excl. Options)
83,662,665
Price
$6.96
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- RLMD on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 83,662,665
- Total 13F value
- $581,479,003
- Portfolio coverage rank
- 0.01%
- Share change
- +30,068,926
- Value change
- +$213,360,580
- Number of holders
- 102
- Shares outstanding
- 104,915,374
- SEC-reported price per share
- $7.21
- Insider filing price
- $7.21
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RLMD - RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 75955J402.
- 102 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 77 to 102 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $245,749,015 to $581,479,003.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 102 institutions filings for Q1 2026.
Security key
75955J402
Latest holder period
Q1 2026
13F holders
102
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
RLMD full holder history
RELMADA THERAPEUTICS, INC. SEC filings
RELMADA THERAPEUTICS, INC. company facts
RELMADA THERAPEUTICS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75955J402:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
RLMD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% | $35,932,374 | 7,439,415 | JANUS HENDERSON GROUP PLC | 30 Jan 2026 | |||
| Squadron Capital Management LLC | 9.9% | 0% | $31,283,007 | +$17,330,352 | 7,395,510 | +124% | Squadron Master Fund LP | 31 Dec 2025 |
| Commodore Capital LP | 5.1% | $40,630,789 | 5,505,527 | Commodore Capital LP | 27 Apr 2026 | |||
| Adage Capital Management, L.P. | 4.5% | -21% | $35,152,106 | +$3,639,506 | 4,763,158 | +12% | Adage Capital Management, L.P. | 31 Mar 2026 |
| Spruce Street Capital LP | 5.6% | $17,284,546 | 4,086,181 | Spruce Street Capital LP | 31 Dec 2025 | |||
| Ikarian Capital, LLC | 4.8% | $7,122,152 | 3,543,359 | Ikarian Capital, LLC | 30 Sep 2025 |
As of 31 Mar 2026, 102 institutional investors reported holding 83,662,665 shares of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (RLMD). This represents 80% of the company’s total 104,915,374 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
68%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 11% | 11,063,862 | +52% | 0.04% | $76,892,206 |
| Squadron Capital Management LLC | 8.1% | 8,474,571 | +26% | 24% | $58,983,014 |
| Spruce Street Capital LP | 6% | 6,262,114 | +53% | 10% | $42,998,208 |
| Venrock Adviser, LLC | 4.6% | 4,843,380 | 1.3% | $33,709,925 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.5% | 4,763,158 | +12% | 0.05% | $33,151,580 |
| ORBIMED ADVISORS LLC | 4.5% | 4,715,864 | +81% | 0.74% | $32,822,413 |
| MARSHALL WACE, LLP | 4.3% | 4,481,606 | +41% | 0.03% | $31,191,980 |
| MILLENNIUM MANAGEMENT LLC | 3.7% | 3,907,265 | +134% | 0.02% | $27,194,564 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.9% | 3,076,570 | 0% | 0% | $21,412,927 |
| RA CAPITAL MANAGEMENT, L.P. | 2.8% | 2,947,369 | 0.22% | $20,513,688 | |
| Ikarian Capital, LLC | 2.6% | 2,688,359 | -12% | 2.7% | $18,710,978 |
| Driehaus Capital Management LLC | 2% | 2,132,053 | +13% | 0.11% | $14,839,089 |
| Polar Capital Holdings Plc | 1.3% | 1,414,621 | 0.04% | $9,845,762 | |
| BlackRock, Inc. | 1.2% | 1,289,550 | +1.7% | 0% | $8,975,269 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.96% | 1,011,572 | +162% | 0.01% | $7,040,541 |
| Sio Capital Management, LLC | 0.92% | 965,000 | 0.97% | $6,716,400 | |
| Opaleye Management Inc. | 0.89% | 935,000 | 0% | 0.9% | $6,507,600 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.81% | 848,683 | -0.73% | 0% | $5,909,987 |
| Soleus Capital Management, L.P. | 0.8% | 842,106 | 0.24% | $5,861,058 | |
| Boxer Capital Management, LLC | 0.8% | 842,106 | 0.77% | $5,861,058 | |
| GREAT POINT PARTNERS LLC | 0.8% | 842,106 | 1.4% | $5,861,058 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.8% | 842,106 | 0.1% | $5,861,058 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.69% | 729,055 | -13% | 0.12% | $5,074,223 |
| Corient Private Wealth LLC | 0.69% | 719,582 | 0% | 0.01% | $4,961,888 |
| ACADIAN ASSET MANAGEMENT LLC | 0.68% | 712,540 | +35% | 0.01% | $4,955,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
26
Latest
Q1 2026
Rows shown
1-25 of 26
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 83,662,665 | $581,479,003 | +$213,360,580 | $6.96 | 102 |
| 2025 Q4 | 50,901,642 | $245,749,015 | +$155,594,501 | $4.83 | 77 |
| 2025 Q3 | 7,739,580 | $15,541,689 | +$5,248,275 | $2.01 | 43 |
| 2025 Q2 | 5,303,151 | $3,177,608 | -$311,761 | $0.60 | 48 |
| 2025 Q1 | 6,219,491 | $1,678,348 | -$765,348 | $0.27 | 43 |
| 2024 Q4 | 8,399,225 | $4,362,564 | -$9,886,723 | $0.52 | 48 |
| 2024 Q3 | 12,376,687 | $40,240,571 | -$3,630,516 | $3.24 | 69 |
| 2024 Q2 | 13,555,167 | $40,671,232 | -$3,047,999 | $3.00 | 78 |
| 2024 Q1 | 14,295,630 | $66,487,069 | +$3,440,282 | $4.65 | 90 |
| 2023 Q4 | 13,621,440 | $56,386,775 | -$3,313,848 | $4.14 | 83 |
| 2023 Q3 | 14,992,668 | $44,979,292 | -$3,168,578 | $3.00 | 87 |
| 2023 Q2 | 16,099,667 | $39,628,526 | -$4,052,287 | $2.46 | 91 |
| 2023 Q1 | 17,764,331 | $40,142,172 | -$4,573,760 | $2.26 | 87 |
| 2022 Q4 | 19,144,470 | $66,816,077 | -$456,735,123 | $3.49 | 106 |
| 2022 Q3 | 25,783,847 | $954,470,507 | +$46,796,895 | $37.02 | 131 |
| 2022 Q2 | 24,632,853 | $467,785,642 | +$33,496,825 | $18.99 | 106 |
| 2022 Q1 | 23,069,358 | $622,305,579 | +$69,498,228 | $26.99 | 107 |
| 2021 Q4 | 20,739,885 | $467,189,248 | +$239,138,409 | $22.53 | 91 |
| 2021 Q3 | 10,023,314 | $262,675,920 | -$4,620,967 | $26.21 | 81 |
| 2021 Q2 | 9,944,006 | $318,306,821 | +$11,580,961 | $32.01 | 83 |
| 2021 Q1 | 9,536,264 | $335,739,251 | +$3,534,612 | $35.21 | 81 |
| 2020 Q4 | 9,311,019 | $298,677,225 | -$48,362,964 | $32.07 | 79 |
| 2020 Q3 | 10,443,239 | $392,874,164 | -$4,538,306 | $37.62 | 72 |
| 2020 Q2 | 10,506,228 | $469,323,200 | +$57,833,259 | $44.75 | 74 |
| 2020 Q1 | 9,357,083 | $319,169,853 | +$94,707,648 | $34.11 | 43 |